OSLO, NORWAY and METUCHEN, NJ (October 17, 2017) – Nattopharma is pleased to announce that it has been selected by Ortho Molecular Products, the leader in practitioner-specific nutraceuticals, as its exclusive Vitamin K2 supplier partner. The company will transition the seven products in its line currently featuring Vitamin K2 to MenaQ7® PRO, a unique line extension available only to Ortho Molecular. For more than 25 years, Ortho Molecular Products has researched and manufactured high-quality, efficacious nutraceuticals sold exclusively to thousands of health care professionals nationwide and in Canada. With headquarters in Chicago, IL, the company has FDA-audited, cGMP-certified manufacturing facilities in Stevens Point, WI, where the company will work to transition the following products to include NattoPharma’s MenaQ7® PRO Vitamin K2:
• Liquid Vitamin D3 with K2
• K-FORCE • Pro Bono
• Alpha Base Capsules without Iron
• Alpha Base Capsules with Iron
“We are proud of our 25 year tradition of successfully combining evidence-based formulations and superior raw ingredients to develop efficacious supplements that noticeably enhance patient health,” says Aaron Bartz, President of Ortho Molecular Products, adding that MenaQ7® was chosen based on the significant data confirming its ability to help the body properly utilize calcium, supporting bone health while simultaneously protecting cardiovascular health. “This partnership with NattoPharma reinforces that commitment, allowing us to provide the practitioner community with the best quality, clinically validated Vitamin K2 as MK-7 available.” “Ortho Molecular Products’ commitment to efficacy, uncompromising manufacturing and legendary customer service has established the company as a leader in the nutrition industry,” says Dan Rosenbaum, NattoPharma CEO. “NattoPharma is honored that this discerning brand recognizes that we are the leader in Vitamin K2 research and development, and that our MenaQ7 Vitamin K2 as MK-7 will allow their practitioner partners to deliver the best possible results for their patients. “We believe we earned the attention of Ortho Molecular Products – and ultimately were selected as a partner – because NattoPharma has been driving the scientific discovery behind the benefits of Vitamin K2,” adds Rosenbaum. “We could not be happier to have Ortho Molecular Products, with its demonstrated years of excellence providing only the best ingredients available, join the NattoPharma family. And we were excited to make available a line extension with MenaQ7 PRO that would speak clearly to the practitioner market.” The reformulated Ortho Molecular Products will be available in 2018.
# # #
About NattoPharma and MenaQ7® NattoPharma ASA, based in Norway, is the world’s leader in vitamin K2 research and development. NattoPharma is the exclusive international supplier of MenaQ7® Vitamin K2 as MK-7, the best documented, vitamin K2 as menaquinone-7 (MK-7) with guaranteed actives and stability, clinical substantiation, and international patents granted and pending. The company has a multi-year research and development program to substantiate and discover the health benefits of vitamin K2 for applications in the marketplace for functional food and dietary supplements. With a global presence, the company established its North American subsidiary, NattoPharma USA, Inc., in Metuchen, NJ, and NattoPharma R&D Ltd. in Cyprus. For more information, visit www.nattopharma.com or www.menaq7.com.
About Ortho Molecular Products For more than 25 years, Ortho Molecular Products has researched and manufactured high-quality, efficacious nutraceuticals sold exclusively to thousands of health care professionals nationwide and in Canada. Ortho Molecular Products is headquartered in the Chicagoland area, with FDA-audited, cGMP-certified manufacturing facilities in Stevens Point, WI. The commitment to efficacy, uncompromising manufacturing and legendary customer service establishes Ortho Molecular Products as a leader in the nutrition industry. To learn more about Ortho Molecular Products, visit www.orthomolecularproducts.com.
For more information, please contact:
Kate Quackenbush, Director of Communications
NattoPharma USA, Inc.